Eisai: Jyseleca (Filgotinib) for Rheumatoid Arthritis Launches in Japan
TOKYO, Nov 18, 2020 – (JCN Newswire) – Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Jyseleca (filgotinib maleate 200 mg and 100 mg tablets), a new once-daily, oral, JAK (Janus kinase) inhibitor that preferentially inhibits JAK1, will be launched in Japan on November 18 for the treatment of rheumatoid arthritis (RA), with... » read more